To print: Select File and then Print from your browser's menu

Title: Combined Eptifibatide/Reduced Tenecteplase Needs Further Study Before General Use In ST-Elevation Myocardial Infarction

URL: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=R
Retrieve&db=PubMed&list_uids=12706917&dopt=Abstract

Journal of the American College of Cardiology 2003;41:8:1251-1260. "Combination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarction: results of the integrilin and tenecteplase in acute myocardial infarction (INTEGRITI) Phase II Angiographic Trial"
04/29/2003 03:09:38 PM
By Elda Hauschildt

Double-bolus eptifibatide plus half-dose tenecteplase (TNK) tends to improve angiographic flow and ST-segment resolution in patients with ST-elevation myocardial infarction (STEMI). Researchers from the United States caution, however, that the combination is also associated with more transfusions and non-cerebral bleeding. Investigators from Brigham and Women's Hospital in Boston, Massachusetts, say that further study is needed before the combination therapy is recommended for general use. Glycoprotein IIb/IIIa inhibitors enhance thrombolysis, but the role of combined therapy in clinical practice has not been established, they explain. A total of 438 patients with STEMI of less than six hours were enrolled. Participants all received aspirin and unfractionated heparin. In the dose-finding section of the study, 189 patients were randomised to different combinations of double-bolus eptifibatide plus reduced-dose TNK. In the dose-confirmation section, 249 patients were randomised one to one to eptifibatide 180 microgram/kg bolus, 2 microgram/kg/min infusion and 180 microgram/kg bolus 10 min later (180/2/180) plus half-dose TNK or to standard dose TNK monotherapy. Thrombolysis in Myocardial Infarction (TIMI) grade 3 epicardial flow at 60 minutes was the primary end point used in the study. TIMI grade 3 flow rates were similar across groups in dose-finding, with arterial patency highest for eptifibatide 180/2/180 plus half-dose TNK. The combination tended to achieve more TIMI 3 flow, arterial patency and ST-segment resolution in dose-confirmation compared to TNK monotherapy. But, the investigators note, combination therapy was also associated with more major haemorrhage and transfusions.

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=R
Retrieve&db=PubMed&list_uids=12706917&dopt=Abstract

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.